AU2017286982B2 - HERV-E reactive T cell receptors and methods of use - Google Patents

HERV-E reactive T cell receptors and methods of use Download PDF

Info

Publication number
AU2017286982B2
AU2017286982B2 AU2017286982A AU2017286982A AU2017286982B2 AU 2017286982 B2 AU2017286982 B2 AU 2017286982B2 AU 2017286982 A AU2017286982 A AU 2017286982A AU 2017286982 A AU2017286982 A AU 2017286982A AU 2017286982 B2 AU2017286982 B2 AU 2017286982B2
Authority
AU
Australia
Prior art keywords
cells
nucleic acid
cell
seq
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017286982A
Other languages
English (en)
Other versions
AU2017286982A1 (en
Inventor
Elena A. CHERKASOVA
Richard W. Childs
Michael I. Nishimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loyola University Chicago
US Department of Health and Human Services
Original Assignee
Loyola University Chicago
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loyola University Chicago, Government of the United States of America filed Critical Loyola University Chicago
Publication of AU2017286982A1 publication Critical patent/AU2017286982A1/en
Application granted granted Critical
Publication of AU2017286982B2 publication Critical patent/AU2017286982B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
AU2017286982A 2016-06-30 2017-06-30 HERV-E reactive T cell receptors and methods of use Active AU2017286982B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357265P 2016-06-30 2016-06-30
US62/357,265 2016-06-30
PCT/US2017/040448 WO2018006054A1 (en) 2016-06-30 2017-06-30 Herv-e reactive t cell receptors and methods of use

Publications (2)

Publication Number Publication Date
AU2017286982A1 AU2017286982A1 (en) 2019-01-17
AU2017286982B2 true AU2017286982B2 (en) 2022-10-13

Family

ID=59381696

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017286982A Active AU2017286982B2 (en) 2016-06-30 2017-06-30 HERV-E reactive T cell receptors and methods of use

Country Status (9)

Country Link
US (1) US11779603B2 (enExample)
EP (1) EP3478711B1 (enExample)
JP (1) JP7046016B2 (enExample)
KR (1) KR102461926B1 (enExample)
CN (1) CN109415429B (enExample)
AU (1) AU2017286982B2 (enExample)
DK (1) DK3478711T3 (enExample)
NZ (1) NZ749585A (enExample)
WO (1) WO2018006054A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111100185A (zh) * 2018-10-26 2020-05-05 上海锐赛生物技术有限公司 Ct-rcc herv-e来源的ctl表位肽、肽库及其应用
CN113710697A (zh) 2019-03-15 2021-11-26 美国政府(由卫生和人类服务部的部长所代表) 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途
WO2021194495A1 (en) 2020-03-26 2021-09-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd28h domain-containing chimeric antigen receptors and methods of use
WO2023044304A1 (en) 2021-09-15 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
WO2025064539A1 (en) * 2023-09-19 2025-03-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Herv-e antibodies and methods of their use
CN118620059B (zh) * 2024-02-21 2025-08-15 北京永泰瑞科生物科技有限公司 一种t细胞抗原受体及其制备方法和其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150152384A1 (en) * 2006-03-17 2015-06-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
EP1224291A1 (en) * 1999-10-28 2002-07-24 Universite De Geneve Multiple sclerosis-related superantigen
DE10019075B4 (de) * 2000-04-18 2007-01-18 Vision 7 Gmbh Verwendung von CD34 oder einem davon abgeleiteten Polypeptid als Zell-Oberflächen- bzw. Gentransfer-Marker
US7820174B2 (en) * 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
SG173997A1 (en) * 2006-07-21 2011-09-29 Univ California Human endogenous retrovirus polypeptide compositions and methods of use thereof
CN101528926A (zh) 2006-08-18 2009-09-09 肿瘤疗法科学股份有限公司 过表达reg4或kiaa0101的癌症的治疗或预防
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
EP2618835B1 (en) * 2010-09-20 2017-07-05 BioNTech Cell & Gene Therapies GmbH Antigen-specific t cell receptors and t cell epitopes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150152384A1 (en) * 2006-03-17 2015-06-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOSHIYUKI TAKAHASHI ET AL, "Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells", JOURNAL OF CLINICAL INVESTIGATION (2008) doi:10.1172/JCI34409 *

Also Published As

Publication number Publication date
JP2019522984A (ja) 2019-08-22
KR20190058389A (ko) 2019-05-29
US20190231821A1 (en) 2019-08-01
DK3478711T3 (da) 2022-12-12
US11779603B2 (en) 2023-10-10
KR102461926B1 (ko) 2022-11-02
NZ749585A (en) 2023-02-24
CN109415429A (zh) 2019-03-01
CN109415429B (zh) 2023-04-28
WO2018006054A1 (en) 2018-01-04
EP3478711B1 (en) 2022-10-12
JP7046016B2 (ja) 2022-04-01
AU2017286982A1 (en) 2019-01-17
EP3478711A1 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
AU2017286982B2 (en) HERV-E reactive T cell receptors and methods of use
KR102802134B1 (ko) 신규한 omni-50 crispr 뉴클레아제
KR102759317B1 (ko) 재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물
JP2024083457A (ja) レンチウイルスベクターのバイオ生産法
CN112225822B (zh) 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用
AU2014374516B2 (en) Construct and sequence for enhanced gene expression
US20030152559A1 (en) Method for the generation of antigen-specific lymphocytes
DK2185696T3 (en) Cells genetically modified to include pancreatic glucokinase, and uses thereof
CN108753807B (zh) 一种重组嵌合抗原受体基因及其应用
CN114324864A (zh) 一种水痘-带状疱疹病毒的IgM和IgG双检免疫层析试纸及应用
AU782255B2 (en) Gene transfer vectors for treating autoimmune diseases and diseases with immunopathogenesis by therapy
KR20200086902A (ko) 신경세포 분화 추적용 벡터 및 이를 이용한 신경세포로의 분화 추적 방법
HK40003218B (en) Herv-e reactive t cell receptors and methods of use
HK40003218A (en) Herv-e reactive t cell receptors and methods of use
CN103864902B (zh) 一种双价dna疫苗连接肽及其应用
IT201900007060A1 (it) Cellule tumorali ingegnerizzate e loro usi
CN113652412A (zh) 一种制备限制性内切酶类产品的方法
US20040076636A1 (en) HIV immunogenic complexes
KR20230085912A (ko) Cd14 프로모터를 갖는 재조합 아데노 관련 바이러스 벡터 및 이의 용도
CN106519005B (zh) 磷酸化nfat3突变体及其应用
US8865421B2 (en) Assays for nuclear hormone receptor binding
CN114480398A (zh) siRNA及其在制备改善和/或治疗白癜风的药物中的应用
KR102721254B1 (ko) 형질전환시킨 중국햄스터난소 세포를 활용하여 시시엔5 단백질을 제조하는 방법
CN115747213A (zh) 一种在基因组上高通量实现tag到taa转换的方法
CN116769811A (zh) 分泌trail的工程化巨噬细胞及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)